SARS-CoV-2 antibody levels after receiving the AstraZeneca or Pfizer-BioNTech vaccine decrease with age and are higher in females and people with prior infection, show data from the Real-time Assessment of Community Transmission (React-2) study.
The study, led by Imperial College London, analysed self-reported results from Fortress lateral flow tests to detect antibodies in a drop of blood from a finger prick. Data were collected from 212 102 adults from January to May 2021, of whom 71 923 (33.9%) had received at least one dose of Pfizer-BioNTech and 139 067 (65.6%) at least one dose of AstraZeneca.
Comments